DAPAFORD 10

(Dapagliflozin 10 mg)

Cardio–Renal–Metabolic Protection Therapy

 

 PRODUCT INTRODUCTION

Brand Name: DAPAFORD 10
Composition: Dapagliflozin 10 mg

Category: SGLT2 Inhibitor – Cardio Renal Protective Agent

CLINICAL BACKGROUND (FOR MR UNDERSTANDING)

Why SGLT2 Inhibitors in CKD & Diabetes?

In diabetic and CKD patients:

• Hyperfiltration damages glomerulus
• Increased intraglomerular pressure
• Albuminuria progression
• Cardio-renal risk rises

👉 SGLT2 inhibitors reduce hyperfiltration and protect nephrons.

MODE OF ACTION (MOA)

• Inhibits Sodium-Glucose Co-Transporter 2 (SGLT2) in proximal tubule
• Reduces glucose reabsorption
• Promotes glucosuria
• Reduces intraglomerular pressure
• Decreases albuminuria

Renal Benefit Mechanism:

✔ Restores tubuloglomerular feedback
✔ Reduces hyperfiltration
✔ Slows CKD progression

INDICATIONS

• Type 2 Diabetes Mellitus
• CKD with or without diabetes
• Heart failure (reduced EF)
• Diabetic nephropathy
• Albuminuria cases

DOSAGE

10 mg once daily
With or without food
As per physician’s advice

FEATURE – ADVANTAGE – BENEFIT (FAB)

🔹 Feature- SGLT2 inhibition

🔹 Advantage- Reduces glucose + protects kidney + cardio benefit

🔹 Benefit-Slows CKD progression & reduces hospitalization risk

USP

✔ Proven cardio-renal protective molecule
✔ Once-daily dosing
✔ Albuminuria reduction
✔ Add-on to RAAS therapy

 

 SAFETY PROFILE

• Genital mycotic infection possible
• Mild diuresis
• Monitor renal function
• Avoid in severe dehydration